89 Imlunestrant With or Without Abemaciclib as First- and Second-Line Therapy in Advanced Breast Cancer (ABC): A Subgroup Analysis From the EMBER-3 Trial
ByPatrick Neven, MD, PhD,Andre Mattar,Antonio Llombart-Cussac,Giuseppe Curigliano,Nadia Harbeck, MD, PhD,Joyce O’Shaughnessy, MD,François-Clément Bidard,Monica Lis Casalnuovo,Sung-Bae Kim,Eriko Tokunaga,Cristina Saura,Lisa A. Carey, MD,Kamnesh R. Pradhan,Shanshan Cao,Monique Coersmeyer,Anna Emde,Francisco Sapunar,Komal L. Jhaveri,Philippe Aftimos